R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana

Published on April 13, 2023

The University of Oxford-developed and Serum Institute of India PvT Ltd (SIIPL)- manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority.
Continue reading on website
Other news

MIT Sloan: Well-Being Intelligence: A Skill Set for the New World of Work

April 13, 2023
Thomas Roulet, Associate Professor in Organisation Theory and Deputy Director of the MBA programme at Cambridge Judge Business School, writes about a rise in workplace mental health issues.Read the full article [sloanreview.mit.edu]The post MIT Sloan: Well-Being Intelligence: A Skill Set for the New World of Work appeared first on Cambridge Judge Business School.

Trial investigating potential treatment for fatigue relief in people with long COVID reports results

April 14, 2023
Researchers from the University of Oxford have reported findings from a Phase 2 clinical trial investigating the efficacy of an investigational treatment against long COVID fatigue.The study (reported in Lancet eClinical Medicine) found participants given the treatment, developed by US pharmaceutical company Axcella Therapeutics, reported feeling less fatigued than those given a placebo.